{"gene":"BRAF","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":2002,"finding":"BRAF somatic missense mutations occur in 66% of malignant melanomas and at lower frequency across many human cancers; all mutations are within the kinase domain, with V599E (V600E) accounting for ~80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. RAS function is not required for growth of cancer cell lines with the V600E mutation.","method":"Genome-wide sequencing screen, in vitro kinase assays, NIH3T3 transformation assay, cell line growth assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original discovery with kinase assays and transformation assays, massively replicated","pmids":["12068308"],"is_preprint":false},{"year":2004,"finding":"Crystal structures of wild-type and oncogenic V599E BRAF kinase domains reveal that the activation segment is held in an inactive conformation by association with the P-loop. Most oncogenic mutations disrupt this inhibitory interaction, converting BRAF to its active conformation. High-activity mutants signal to ERK by directly phosphorylating MEK, whereas kinase-impaired mutants stimulate MEK by activating endogenous C-RAF, possibly via allosteric or transphosphorylation mechanisms.","method":"X-ray crystallography of BRAF kinase domain (WT and V599E), in vitro kinase assays of 22 BRAF mutants, ERK signaling assays in cells","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure combined with functional mutagenesis and kinase assays, foundational mechanism paper","pmids":["15035987"],"is_preprint":false},{"year":2005,"finding":"BRAF(V600E) expression in primary human melanocytes induces cell cycle arrest with hallmarks of oncogene-induced senescence (OIS), including p16(INK4a) induction and senescence-associated beta-galactosidase activity. Congenital naevi are invariably positive for SA-beta-Gal in vivo, demonstrating that BRAF(V600E) drives senescence rather than proliferation in the benign lesion context.","method":"Retroviral expression of BRAF(V600E) in human melanocytes, SA-beta-Gal assay, p16(INK4a) immunostaining, in vivo nevi analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean loss/gain-of-function with defined cellular phenotype, validated in vivo, replicated by subsequent studies","pmids":["16079850"],"is_preprint":false},{"year":2010,"finding":"ATP-competitive RAF inhibitors have two opposing mechanisms depending on cellular context: in BRAF(V600E) tumors they block MAPK signaling, but in KRAS-mutant or RAS/RAF wild-type tumors they activate the RAF-MEK-ERK pathway by inducing wild-type RAF dimerization, membrane localization, and interaction with RAS-GTP—events linked to conformational effects on the RAF kinase domain independent of kinase inhibition.","method":"Cellular signaling assays in multiple tumor cell lines and xenograft models, biochemical studies of RAF dimerization, membrane fractionation, co-immunoprecipitation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, replicated across labs, mechanistic basis for paradoxical activation","pmids":["20130576"],"is_preprint":false},{"year":2010,"finding":"Kinase-dead BRAF, when present with oncogenic RAS, drives MEK-ERK signaling and tumor progression through CRAF. BRAF-selective drugs promote RAS-dependent BRAF binding to CRAF and CRAF activation specifically when oncogenic RAS is present. Kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.","method":"Genetic mouse model (kinase-dead Braf + oncogenic Ras), CRAF co-immunoprecipitation, MEK-ERK phosphorylation assays, siRNA knockdown, mouse melanoma model","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo mouse model plus biochemical mechanism, replicated concept across multiple studies","pmids":["20141835"],"is_preprint":false},{"year":2014,"finding":"Copper (Cu) is required for oncogenic BRAF(V600E) signaling and tumorigenesis. CTR1 (Cu transporter 1) deficiency or MEK1 mutations disrupting Cu binding decreased BRAF(V600E)-driven signaling and tumor growth. A MEK1-MEK5 chimera that phosphorylated ERK1/2 independently of Cu, or active ERK2, restored tumor growth in Ctr1-deficient cells. Cu chelators reduced BRAF(V600E)-driven tumor growth.","method":"CTR1 knockdown/knockout in mouse and human cells, MEK1 Cu-binding mutants, rescue experiments, tumor xenograft/mouse models, Cu chelation treatment","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacologic approaches, in vivo validation","pmids":["24717435"],"is_preprint":false},{"year":2015,"finding":"Oncogenic BRAF V600E upregulates the ketogenic enzyme HMGCL through octamer transcription factor Oct-1, leading to increased intracellular acetoacetate. Acetoacetate selectively enhances binding of BRAF(V600E) but not wild-type BRAF to MEK1, promoting MEK-ERK signaling activation in a V600E-specific manner. HMGCL suppression specifically attenuates proliferation and tumor growth in BRAF(V600E)-expressing cells.","method":"Metabolomics, co-immunoprecipitation of BRAF(V600E)/BRAF-WT with MEK1, HMGCL knockdown/overexpression, Oct-1 transcription factor assays, xenograft tumor models","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical binding assay distinguishing V600E vs WT, multiple orthogonal methods, in vivo validation","pmids":["26145173"],"is_preprint":false},{"year":2016,"finding":"BRAF(V600E) drives melanoma cell invasion by inducing phosphorylation of cortactin and the exocyst subunit Exo70 through ERK, which regulates actin dynamics (F-actin and cortactin foci/invadopodia) and matrix metalloprotease secretion, respectively. BRAF(V600E) inhibition blocks invasion, decreases cortactin foci in murine melanoma models and patient biopsies, and downregulates invadopodia-related genes.","method":"F-actin/cortactin imaging, matrix degradation assays, ERK substrate phosphorylation analysis, BRAF(V600E) inhibitor treatment, murine model and patient biopsies, genome-wide expression analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway placement with defined substrates, in vitro and in vivo validation","pmids":["27210749"],"is_preprint":false},{"year":2017,"finding":"Kinase-inactive BRAF(D631A) (corresponding to human BRAF(D594A)) acts as an oncogenic initiating event in lung adenocarcinoma in vivo. Co-expression with Kras(G12V) enhances tumor initiation via Craf kinase activity. Wild-type Braf kinase is required to sustain these tumors; its ablation causes excessive MAPK signaling leading to oncogenic toxicity, which can be reversed by MEK inhibition. Loss of wild-type Braf also triggers transdifferentiation of club cells.","method":"Conditional knock-in mouse models, Cre-mediated activation, genetic Braf ablation, pharmacological MEK inhibition, histopathological analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — sophisticated in vivo mouse genetics with multiple genetic interventions and defined phenotypes","pmids":["28783725"],"is_preprint":false},{"year":2018,"finding":"PLX8394 inhibits ERK signaling by specifically disrupting BRAF-containing dimers (BRAF homodimers and BRAF-CRAF heterodimers) but not CRAF homodimers or ARAF-containing dimers. Differences in the N-terminal portion of the kinase domain among RAF isoforms determine this differential vulnerability. PLX8394 selectively inhibits ERK signaling in tumors driven by dimeric BRAF mutants, including fusions, splice variants, and V600 monomers, but spares CRAF-homodimer-driven signaling in normal cells.","method":"Cell-based ERK signaling assays, selective dimer disruption biochemistry, comparisons across RAF isoforms, tumor cell line panels with varied BRAF mutations","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection of dimer-specific signaling with isoform mutagenesis and pharmacological validation","pmids":["30559419"],"is_preprint":false},{"year":2019,"finding":"BRAF inhibitors stabilize an intermediate, inactive kinase conformation of BRAF(V600E) that enhances binary RAS:RAF interactions independently of RAF dimerization in melanoma cells. This represents an allosteric effect of drug-driven intramolecular communication between the kinase and RAS-binding domains of mutated BRAF, which may promote paradoxical kinase activation and drug resistance.","method":"Luciferase-based BRAF conformation biosensors, RAS:RAF interaction assays, melanoma cell RAF dimerization studies, structurally diverse inhibitor panel","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 — novel biosensor approach with pharmacological validation, single lab","pmids":["31453322"],"is_preprint":false},{"year":2020,"finding":"BRAF(D594G), a kinase-dead class 3 mutant, has higher dimerization potential than wild-type BRAF. Molecular dynamics simulations show the D594G substitution orients the αC-helix toward the IN position and extends the activation loop, shifting equilibrium toward the active dimeric conformation, priming BRAF(D594G) as an allosteric activator of CRAF. BRAF/CRAF heterodimers are the most thermodynamically stable RAF dimers. BRAF(D594G):CRAF heterodimers bypass autoinhibitory P-loop phosphorylation.","method":"Cell biology, biochemical dimerization assays, molecular dynamics simulations, P-loop phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical plus computational approach, single lab","pmids":["31929109"],"is_preprint":false},{"year":2020,"finding":"Ponatinib inhibits BRAF monomers and dimers by binding to an allosteric site that stabilizes a distinct αC-helix conformation. Using structural insights from ponatinib, a BRAF inhibitor PHI1 was developed that selectively inhibits BRAF dimers, with enhanced inhibition of the second protomer when the first is occupied (positively cooperative dimer inhibition), defining a novel class of dimer-selective inhibitors.","method":"Structural analysis, cell-based BRAF dimer selectivity assays, medicinal chemistry/compound development, ERK signaling assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — structural and functional dimer inhibition data, single lab","pmids":["32873792"],"is_preprint":false},{"year":2022,"finding":"The acetyltransferase p300 activates BRAF kinase by promoting BRAF K601 acetylation, a process antagonized by the deacetylase SIRT1. K601 acetylation facilitates BRAF dimerization with RAF proteins and KSR1, promotes melanoma cell proliferation, and contributes to BRAF(V600E) inhibitor resistance. The oncogenic K601E mutation mimics K601 acetylation to augment BRAF kinase activity.","method":"Acetylation assays, p300/SIRT1 co-immunoprecipitation, BRAF dimerization assays, cell proliferation and drug resistance assays, K601E mutation analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — identified writer (p300) and eraser (SIRT1) of a PTM with functional validation, single lab","pmids":["35045286"],"is_preprint":false},{"year":2019,"finding":"Peptide inhibitors targeting the BRAF dimer interface potently inhibit kinase activity of BRAF homo- and heterodimers, including oncogenic BRAF(G469A). Targeting the dimer interface leads to protein degradation of both RAF and MEK, revealing a novel scaffolding function of RAF in protecting large MAPK signaling complexes from proteasomal degradation.","method":"In silico peptide design, in vitro kinase assays on BRAF homo/heterodimers, protein stability assays, RAF/MEK degradation studies in cancer cells","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro kinase assays plus cellular scaffolding function discovery, single lab","pmids":["31243962"],"is_preprint":false},{"year":2011,"finding":"TSC22D1 short transcript is upregulated >100-fold in BRAF(E600)-induced senescence in human fibroblasts and melanocytes, while the large TSC22D1 protein variant is suppressed by proteasomal degradation. Selective depletion of the short form, or overexpression of the large form, abrogates OIS and suppresses inflammatory factors and p15(INK4B). TSC22D1 is a critical effector of C/EBPβ in BRAF(V600E)-driven OIS.","method":"Gene expression profiling, shRNA knockdown, overexpression experiments, senescence assays (SA-beta-Gal, p16/p15 staining) in human fibroblasts and melanocytes","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockdown and overexpression with defined senescence phenotypes, single lab","pmids":["21448135"],"is_preprint":false},{"year":2018,"finding":"Oncogenic BRAF and AXL drive loss of RIPK3 expression in cancer cells, leading to resistance to necroptosis. Inhibition of BRAF (or AXL) rescues RIPK3 expression and restores necroptosis sensitivity, placing BRAF as an oncogenic driver that suppresses the RIPK1-RIPK3-MLKL necroptosis pathway.","method":"Genome-wide bioinformatics screen of 941 cancer cell lines, BRAF/AXL inhibitor treatment, RIPK3 expression rescue assays, necroptosis sensitivity assays","journal":"PLoS biology","confidence":"Medium","confidence_rationale":"Tier 2 — large-scale screen with pharmacological validation, single lab","pmids":["30157175"],"is_preprint":false},{"year":2006,"finding":"BRAF(V600E) signaling through MEK1/2 upregulates ERK3/MAPK6 expression. ERK3 protein is unstable and rapidly degraded upon pharmacological BRAF inhibition. In melanoma cells, RNAi knockdown of BRAF or MEK inhibitor treatment reduces ERK3 levels, demonstrating ERK3 as a downstream transcriptional target of the BRAF-MEK axis.","method":"Conditionally active BRAF(V600E) expression system, microarray expression profiling, pharmacological BRAF/MEK inhibition, RNAi knockdown, protein stability assays","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 — conditional expression system plus RNAi and inhibitor validation, single lab","pmids":["16964379"],"is_preprint":false},{"year":2018,"finding":"ERK5 expression, phosphorylation, and nuclear localization are positively regulated by oncogenic BRAF(V600E). Both ERK5 kinase and transcriptional transactivator activities are enhanced by BRAF. Nuclear ERK5 is critical for cell proliferation in melanoma, and combined pharmacological inhibition of BRAF(V600E) and MEK5 is required to decrease nuclear ERK5 and achieve greater anti-tumor efficacy.","method":"ERK5 knockdown, pharmacological inhibition of BRAF(V600E)/MEK5/ERK5, subcellular fractionation/localization assays, colony formation, xenograft models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — multiple inhibitors and genetic knockdown with defined nuclear localization phenotype, single lab","pmids":["29483645"],"is_preprint":false},{"year":2010,"finding":"Acquired resistance to PLX4032 (vemurafenib) in BRAF(V600E) melanoma develops through mutually exclusive PDGFRβ upregulation or NRAS mutations, but not through secondary mutations in BRAF(V600E). PDGFRβ-upregulated cells maintain low activated RAS and do not reactivate MAPK upon PLX4032 treatment, while NRAS-mutant resistant cells show significant MAPK reactivation and MEK inhibitor sensitivity.","method":"PLX4032-resistant subline derivation, patient biopsy analysis, PDGFRβ/NRAS knockdown and overexpression, MAPK pathway signaling assays, patient-derived short-term cultures","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clinical samples plus cell line mechanistic studies, validated in patient biopsies, independently replicated concept","pmids":["21107323"],"is_preprint":false},{"year":2010,"finding":"MAP3K8 (COT/Tpl2) drives resistance to RAF inhibition in BRAF(V600E) melanoma by activating ERK through MEK-dependent mechanisms that do not require RAF signaling. COT expression is associated with de novo and acquired resistance in BRAF(V600E) cell lines and patient-derived relapsing tumor tissue.","method":"Kinase ORF expression screen (~600 kinases), patient biopsy analysis, MEK/ERK signaling assays, COT inhibition studies","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — large-scale functional screen validated in patient samples and cell lines","pmids":["21107320"],"is_preprint":false},{"year":2019,"finding":"In response to dual BRAF/MEK inhibitor treatment, transcriptional upregulation of FGF1 results in autocrine activation of FGFR, which reactivates ERK as an adaptive resistance mechanism. FGFR inhibition overcomes resistance to dual BRAF/MEK inhibitors in cell lines and patient-derived xenograft models.","method":"Drug-resistant cell line generation, pharmacologic synthetic lethal screen, FGF1 expression analysis, FGFR inhibition rescue experiments, PDX models","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis with PDX validation, single lab","pmids":["31515463"],"is_preprint":false}],"current_model":"BRAF is a RAS-regulated serine/threonine kinase that, in its active conformation (disrupted by oncogenic mutations such as V600E), directly phosphorylates MEK to activate the ERK MAPK pathway; V600E functions as a constitutively active monomer while kinase-impaired class 3 mutants signal allosterically through CRAF dimers, and wild-type BRAF activity is modulated by RAS-GTP-driven dimerization, copper-dependent MEK interactions, acetylation at K601 by p300 (reversed by SIRT1), and inhibitor-induced conformational changes that can paradoxically activate signaling in RAS-mutant cells."},"narrative":{"teleology":[{"year":2002,"claim":"The discovery that BRAF is the most frequently mutated kinase in melanoma established it as a direct oncogenic driver, with V600E accounting for ~80% of mutations and conferring constitutive kinase activity independent of RAS.","evidence":"Genome-wide cancer mutation screen, in vitro kinase assays, NIH3T3 transformation assay across hundreds of tumor samples","pmids":["12068308"],"confidence":"High","gaps":["Structural basis of how V600E activates the kinase was unknown","Whether mutant BRAF could be therapeutically targeted was untested"]},{"year":2004,"claim":"Crystallography of the BRAF kinase domain revealed that the P-loop–activation segment interaction maintains autoinhibition and that oncogenic mutations disrupt this interaction; critically, kinase-impaired mutants were shown to activate ERK through CRAF rather than directly phosphorylating MEK, establishing two mechanistically distinct classes of BRAF oncogenic mutations.","evidence":"X-ray crystallography of WT and V599E BRAF kinase domains, in vitro kinase assays of 22 mutants, cellular ERK signaling assays","pmids":["15035987"],"confidence":"High","gaps":["Precise mechanism by which kinase-dead BRAF activates CRAF (allosteric vs. transphosphorylation) was unresolved","No co-structure of BRAF dimers available"]},{"year":2005,"claim":"Demonstrating that BRAF(V600E) triggers oncogene-induced senescence rather than proliferation in primary melanocytes resolved the paradox of why BRAF mutations are found in benign nevi, establishing a tumor-suppressive barrier that must be overcome for melanoma progression.","evidence":"Retroviral V600E expression in human melanocytes, SA-β-Gal and p16(INK4a) staining, in vivo nevi analysis","pmids":["16079850"],"confidence":"High","gaps":["Which cooperating lesions allow escape from OIS was not defined","Molecular effectors downstream of BRAF in the senescence program were incompletely mapped"]},{"year":2010,"claim":"Three concurrent studies resolved how RAF inhibitors paradoxically activate ERK in RAS-mutant cells (via drug-induced wild-type RAF dimerization), how kinase-dead BRAF cooperates with oncogenic RAS through CRAF activation in vivo, and how clinical resistance to vemurafenib arises through PDGFRβ upregulation or NRAS mutations—collectively defining the dimerization-dependent and bypass mechanisms that limit monotherapy efficacy.","evidence":"Cellular signaling across tumor line panels, co-immunoprecipitation, membrane fractionation, conditional mouse models (kinase-dead Braf + oncogenic Ras), patient biopsies, resistant subline derivation","pmids":["20130576","20141835","21107323","21107320"],"confidence":"High","gaps":["Whether dimer-breaking compounds could overcome paradoxical activation was untested","Full landscape of resistance mechanisms in patients was incomplete"]},{"year":2011,"claim":"Identification of TSC22D1 as a critical effector of C/EBPβ in BRAF(V600E)-driven OIS provided the first molecular link between the BRAF-ERK pathway and the transcriptional senescence program in melanocytes.","evidence":"Gene expression profiling, shRNA knockdown and overexpression in human fibroblasts/melanocytes, SA-β-Gal and p15 assays","pmids":["21448135"],"confidence":"Medium","gaps":["Whether TSC22D1 is required for OIS in vivo was not tested","Other senescence effectors downstream of BRAF were not systematically mapped"]},{"year":2014,"claim":"Showing that copper, via CTR1, is required for BRAF(V600E)-driven MEK phosphorylation and tumorigenesis introduced a metabolic cofactor dependency into the MAPK signaling model and provided a rationale for copper chelation as a therapeutic strategy.","evidence":"CTR1 knockout/knockdown, MEK1 Cu-binding mutants, rescue experiments, tumor xenograft and mouse models, Cu chelation","pmids":["24717435"],"confidence":"High","gaps":["Direct structural evidence of Cu binding to MEK in the BRAF–MEK complex was lacking","Clinical utility of Cu chelation was not established"]},{"year":2015,"claim":"Discovery that BRAF(V600E) upregulates the ketogenic enzyme HMGCL, leading to acetoacetate accumulation that selectively enhances V600E–MEK1 binding, revealed an unexpected metabolic feed-forward loop specific to the oncogenic mutant.","evidence":"Metabolomics, co-immunoprecipitation of BRAF variants with MEK1, HMGCL knockdown/overexpression, xenograft models","pmids":["26145173"],"confidence":"High","gaps":["Structural basis of acetoacetate-enhanced V600E–MEK1 binding was unknown","Relevance beyond melanoma not tested"]},{"year":2016,"claim":"Mapping BRAF(V600E)-driven invasion to ERK-dependent phosphorylation of cortactin (actin remodeling/invadopodia) and Exo70 (MMP secretion) extended the functional repertoire of oncogenic BRAF from proliferation and senescence to metastatic cell behavior.","evidence":"F-actin/cortactin imaging, matrix degradation assays, BRAF inhibitor treatment in murine models and patient biopsies","pmids":["27210749"],"confidence":"High","gaps":["Whether these effectors are relevant in non-melanoma BRAF-driven cancers was not addressed","Direct ERK phosphorylation sites on cortactin and Exo70 were not fully mapped"]},{"year":2017,"claim":"In vivo demonstration that kinase-dead BRAF(D594A) initiates lung adenocarcinoma and that wild-type BRAF is required to buffer MAPK output—its loss causing lethal ERK hyperactivation—established that BRAF functions both as an allosteric activator and a homeostatic regulator of MAPK flux.","evidence":"Conditional knock-in mouse models with genetic Braf ablation and pharmacological MEK inhibition","pmids":["28783725"],"confidence":"High","gaps":["Whether this buffering role applies in tissues other than lung was not tested","Mechanism by which wild-type BRAF limits CRAF output was not structurally resolved"]},{"year":2018,"claim":"Concurrent studies showed that oncogenic BRAF suppresses necroptosis by silencing RIPK3 and upregulates nuclear ERK5 transcriptional activity, broadening the downstream effector landscape beyond canonical ERK1/2; additionally, PLX8394 was shown to selectively disrupt BRAF-containing dimers without affecting CRAF homodimers, providing a pharmacological proof-of-concept for dimer-selective RAF inhibition.","evidence":"Genome-wide screen of 941 cancer cell lines for RIPK3 loss, BRAF/AXL inhibitor rescue of necroptosis; ERK5 subcellular fractionation and combined BRAF/MEK5 inhibition; PLX8394 dimer disruption biochemistry across RAF isoforms","pmids":["30157175","29483645","30559419"],"confidence":"High","gaps":["Whether RIPK3 silencing is epigenetic or transcriptional was not determined","ERK5-specific transcriptional targets downstream of BRAF were not identified","PLX8394 clinical efficacy in dimer-driven tumors was untested"]},{"year":2019,"claim":"Three advances refined the mechanistic picture: BRAF inhibitors were shown to stabilize an intermediate kinase conformation that allosterically enhances RAS–RAF binding independently of dimerization; peptide-mediated disruption of the BRAF dimer interface triggered proteasomal degradation of both RAF and MEK, revealing a scaffolding function; and FGF1–FGFR autocrine reactivation was identified as an adaptive resistance mechanism to combined BRAF/MEK inhibition.","evidence":"Luciferase-based BRAF conformation biosensors in melanoma cells; in silico peptide design with in vitro kinase and protein stability assays; drug-resistant cell line generation with FGFR inhibition in PDX models","pmids":["31453322","31243962","31515463"],"confidence":"Medium","gaps":["Allosteric RAS–RAF enhancement awaits structural resolution","Scaffolding function of RAF dimers not confirmed in vivo","Clinical validation of FGFR co-inhibition in BRAF-mutant patients was lacking"]},{"year":2020,"claim":"Molecular dynamics and biochemical studies of class 3 mutant BRAF(D594G) demonstrated that the mutation shifts αC-helix orientation toward the active state, increasing dimerization potential and priming allosteric CRAF activation while bypassing P-loop autoinhibition; separately, a cooperative dimer-selective BRAF inhibitor (PHI1) was developed using structural insights from ponatinib, defining a new pharmacological class.","evidence":"MD simulations, biochemical dimerization/P-loop phosphorylation assays; structural analysis and medicinal chemistry with cell-based ERK assays","pmids":["31929109","32873792"],"confidence":"Medium","gaps":["No experimental structure of D594G dimer was obtained","PHI1 not tested in vivo or in clinical samples"]},{"year":2022,"claim":"Identification of p300-mediated acetylation at K601 (reversed by SIRT1) as a direct activating modification of BRAF that promotes dimerization with RAF/KSR1 and confers BRAF inhibitor resistance added a post-translational regulatory layer to the dimerization-dependent activation model and explained the oncogenic K601E mutation as an acetylation mimic.","evidence":"Acetylation assays, p300/SIRT1 co-immunoprecipitation, BRAF dimerization and drug resistance assays, K601E mutation analysis","pmids":["35045286"],"confidence":"Medium","gaps":["In vivo relevance of K601 acetylation in tumor progression not tested","Whether other acetyltransferases contribute is unknown","Structural basis of acetylation-enhanced dimerization not resolved"]},{"year":null,"claim":"Key unresolved questions include the full structural basis of RAS-driven BRAF dimerization at the membrane, the determinants of tissue-specific responses to kinase-dead BRAF alleles, and whether dimer-selective or cooperative RAF inhibitors can achieve durable clinical responses without paradoxical activation.","evidence":"","pmids":[],"confidence":"High","gaps":["No full-length BRAF structure in complex with RAS at the membrane","Tissue-specific determinants of kinase-dead BRAF oncogenicity are undefined","Clinical durability of next-generation RAF inhibitors remains untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,6,7,13]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,5,6]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,8,14]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,3,11]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,3,4,5,6,9,10,11,12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,2,7,16,19,20,21]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,16]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,15]}],"complexes":["BRAF-CRAF heterodimer","BRAF homodimer","BRAF-KSR1 complex","RAF-MEK-ERK signaling complex"],"partners":["CRAF","MEK1","MEK2","KSR1","KRAS","EP300","SIRT1","ARAF"],"other_free_text":[]},"mechanistic_narrative":"BRAF is a RAS-regulated serine/threonine kinase that serves as the principal activator of the MEK–ERK MAPK cascade, governing cell proliferation, differentiation, senescence, and survival. Its kinase domain adopts an autoinhibited conformation in which the activation segment associates with the P-loop; oncogenic mutations—most commonly V600E—disrupt this interaction, yielding a constitutively active monomer that directly phosphorylates MEK, whereas kinase-impaired (class 3) mutants such as D594G signal allosterically through RAS-dependent BRAF–CRAF heterodimers [PMID:15035987, PMID:31929109]. BRAF activity is further modulated by p300-mediated acetylation at K601 (reversed by SIRT1), which promotes RAF dimerization and drug resistance, and by copper availability through CTR1, which is required for productive MEK phosphorylation [PMID:35045286, PMID:24717435]. Somatic BRAF mutations—found in ~66% of melanomas and many other cancers—drive tumorigenesis but also trigger oncogene-induced senescence in primary melanocytes; acquired resistance to BRAF inhibitors arises through NRAS mutation, PDGFRβ upregulation, COT/MAP3K8 expression, or FGF1–FGFR reactivation, while first-generation ATP-competitive RAF inhibitors paradoxically activate MAPK in RAS-mutant cells by promoting wild-type RAF dimerization [PMID:12068308, PMID:16079850, PMID:20130576, PMID:21107323]."},"prefetch_data":{"uniprot":{"accession":"P15056","full_name":"Serine/threonine-protein kinase B-raf","aliases":["Proto-oncogene B-Raf","p94","v-Raf murine sarcoma viral oncogene homolog B1"],"length_aa":766,"mass_kda":84.4,"function":"Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)","subcellular_location":"Nucleus; Cytoplasm; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P15056/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BRAF","classification":"Not Classified","n_dependent_lines":115,"n_total_lines":1208,"dependency_fraction":0.09519867549668874},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"MAP2K1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BRAF","total_profiled":1310},"omim":[{"mim_id":"620929","title":"MOB KINASE ACTIVATOR 3A; MOB3A","url":"https://www.omim.org/entry/620929"},{"mim_id":"620412","title":"NONCODING RNA ASSOCIATED WITH MAP KINASE PATHWAY AND GROWTH ARREST; NAMA","url":"https://www.omim.org/entry/620412"},{"mim_id":"619589","title":"BRAF-ACTIVATED NONCODING RNA; BANCR","url":"https://www.omim.org/entry/619589"},{"mim_id":"617108","title":"SESSILE SERRATED POLYPOSIS CANCER SYNDROME; SSPCS","url":"https://www.omim.org/entry/617108"},{"mim_id":"617057","title":"CYTOSOLIC THIOURIDYLASE, SUBUNIT 2; CTU2","url":"https://www.omim.org/entry/617057"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Centriolar satellite","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"},{"location":"End piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRAF"},"hgnc":{"alias_symbol":["BRAF1","BRAF-1"],"prev_symbol":[]},"alphafold":{"accession":"P15056","domains":[{"cath_id":"3.10.20.90","chopping":"155-225","consensus_level":"medium","plddt":85.9792,"start":155,"end":225},{"cath_id":"3.30.60.20","chopping":"236-290","consensus_level":"medium","plddt":82.2804,"start":236,"end":290},{"cath_id":"3.30.200.20","chopping":"450-531","consensus_level":"medium","plddt":85.9628,"start":450,"end":531},{"cath_id":"1.10.510.10","chopping":"535-721","consensus_level":"medium","plddt":88.0211,"start":535,"end":721},{"cath_id":"1.10.287","chopping":"43-102","consensus_level":"high","plddt":81.6427,"start":43,"end":102}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15056","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15056-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15056-F1-predicted_aligned_error_v6.png","plddt_mean":66.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRAF","jax_strain_url":"https://www.jax.org/strain/search?query=BRAF"},"sequence":{"accession":"P15056","fasta_url":"https://rest.uniprot.org/uniprotkb/P15056.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15056/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15056"}},"corpus_meta":[{"pmid":"12068308","id":"PMC_12068308","title":"Mutations of the BRAF gene in human cancer.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12068308","citation_count":8350,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23020132","id":"PMC_23020132","title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23020132","citation_count":2209,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25265494","id":"PMC_25265494","title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.","date":"2014","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25265494","citation_count":1652,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25265492","id":"PMC_25265492","title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.","date":"2014","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25265492","citation_count":1504,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21663470","id":"PMC_21663470","title":"BRAF mutations in hairy-cell leukemia.","date":"2011","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21663470","citation_count":802,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22554099","id":"PMC_22554099","title":"The role of BRAF V600 mutation in melanoma.","date":"2012","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22554099","citation_count":598,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25787767","id":"PMC_25787767","title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.","date":"2015","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25787767","citation_count":481,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29431699","id":"PMC_29431699","title":"Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.","date":"2018","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29431699","citation_count":477,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24717435","id":"PMC_24717435","title":"Copper is required for oncogenic BRAF signalling and tumorigenesis.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24717435","citation_count":460,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30351999","id":"PMC_30351999","title":"BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.","date":"2018","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30351999","citation_count":273,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24859340","id":"PMC_24859340","title":"Identification of recurrent SMO and BRAF mutations in ameloblastomas.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24859340","citation_count":265,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32540454","id":"PMC_32540454","title":"Clinical Development of BRAF plus MEK Inhibitor Combinations.","date":"2020","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32540454","citation_count":259,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24993163","id":"PMC_24993163","title":"Activating FGFR2-RAS-BRAF mutations in ameloblastoma.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24993163","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17724477","id":"PMC_17724477","title":"BRAF(E600) in benign and malignant human tumours.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17724477","citation_count":214,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27429963","id":"PMC_27429963","title":"Resistant mechanisms to BRAF inhibitors in melanoma.","date":"2016","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27429963","citation_count":181,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16845322","id":"PMC_16845322","title":"BRAF and NRAS mutations in melanoma and melanocytic nevi.","date":"2006","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/16845322","citation_count":181,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30559419","id":"PMC_30559419","title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.","date":"2018","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30559419","citation_count":159,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15048078","id":"PMC_15048078","title":"Microarray expression profiling in melanoma reveals a BRAF mutation signature.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15048078","citation_count":147,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26145173","id":"PMC_26145173","title":"Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26145173","citation_count":133,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32645969","id":"PMC_32645969","title":"BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32645969","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23594689","id":"PMC_23594689","title":"Clinicopathological relevance of BRAF mutations in human cancer.","date":"2013","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23594689","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25624498","id":"PMC_25624498","title":"BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25624498","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25344914","id":"PMC_25344914","title":"Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25344914","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21900390","id":"PMC_21900390","title":"Role of BRAF in thyroid oncogenesis.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21900390","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23242278","id":"PMC_23242278","title":"To BRAF or not to BRAF: is that even a question anymore?","date":"2013","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23242278","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29114545","id":"PMC_29114545","title":"Overcoming resistance to BRAF inhibitors.","date":"2017","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29114545","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26498038","id":"PMC_26498038","title":"Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26498038","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28783725","id":"PMC_28783725","title":"A Braf kinase-inactive mutant induces lung adenocarcinoma.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28783725","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16567964","id":"PMC_16567964","title":"BRAF somatic mutations in malignant melanoma and melanocytic naevi.","date":"2006","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/16567964","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23617957","id":"PMC_23617957","title":"B-Raf and the inhibitors: from bench to bedside.","date":"2013","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23617957","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16299399","id":"PMC_16299399","title":"Alterations of the BRAF gene in thyroid tumors.","date":"2005","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16299399","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29461827","id":"PMC_29461827","title":"Current Insights of BRAF Inhibitors in Cancer.","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29461827","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36842301","id":"PMC_36842301","title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy.","date":"2023","source":"ESMO open","url":"https://pubmed.ncbi.nlm.nih.gov/36842301","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33801689","id":"PMC_33801689","title":"BRAF Gene and Melanoma: Back to the Future.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33801689","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23549875","id":"PMC_23549875","title":"Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23549875","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30157175","id":"PMC_30157175","title":"BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.","date":"2018","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/30157175","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25385327","id":"PMC_25385327","title":"Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25385327","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18337114","id":"PMC_18337114","title":"Clinical implications of BRAF mutation in thyroid carcinoma.","date":"2008","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/18337114","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34636352","id":"PMC_34636352","title":"BRAF mutations in thyroid cancer.","date":"2022","source":"Current opinion in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34636352","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18644254","id":"PMC_18644254","title":"Therapeutic strategies for inhibiting oncogenic BRAF signaling.","date":"2008","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18644254","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32873792","id":"PMC_32873792","title":"Inhibitors of BRAF dimers using an allosteric site.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32873792","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29674508","id":"PMC_29674508","title":"Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29674508","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31398831","id":"PMC_31398831","title":"Atypical BRAF and NRAS Mutations in Mucosal Melanoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31398831","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26563980","id":"PMC_26563980","title":"ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.","date":"2015","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26563980","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24433452","id":"PMC_24433452","title":"Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24433452","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27747083","id":"PMC_27747083","title":"RAS and BRAF in metastatic colorectal cancer management.","date":"2016","source":"Journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27747083","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29483645","id":"PMC_29483645","title":"ERK5 is activated by oncogenic BRAF and promotes melanoma growth.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29483645","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25581727","id":"PMC_25581727","title":"BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.","date":"2015","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25581727","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32485528","id":"PMC_32485528","title":"A BRAF new world.","date":"2020","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/32485528","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33747149","id":"PMC_33747149","title":"BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer.","date":"2021","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33747149","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33268358","id":"PMC_33268358","title":"BRAF inhibition protects against hearing loss in mice.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33268358","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27210749","id":"PMC_27210749","title":"Oncogenic BRAF-Mediated Melanoma Cell Invasion.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27210749","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31243962","id":"PMC_31243962","title":"Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.","date":"2019","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31243962","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31515463","id":"PMC_31515463","title":"Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31515463","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34304249","id":"PMC_34304249","title":"Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34304249","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21818706","id":"PMC_21818706","title":"Targeting oncogenic BRAF in human cancer.","date":"2012","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21818706","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28679432","id":"PMC_28679432","title":"New somatic BRAF splicing mutation in Langerhans cell histiocytosis.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28679432","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32476297","id":"PMC_32476297","title":"BRAF mutation and its inhibitors in sarcoma treatment.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32476297","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36759733","id":"PMC_36759733","title":"A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.","date":"2023","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36759733","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34063682","id":"PMC_34063682","title":"Targeting BRAF and RAS in Colorectal Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34063682","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27169980","id":"PMC_27169980","title":"BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.","date":"2016","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27169980","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35413124","id":"PMC_35413124","title":"Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.","date":"2022","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35413124","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33558987","id":"PMC_33558987","title":"BRAF Heterogeneity in Melanoma.","date":"2021","source":"Current treatment options in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33558987","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22349616","id":"PMC_22349616","title":"Autoantibodies to PAD4 and BRAF in rheumatoid arthritis.","date":"2012","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22349616","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26851802","id":"PMC_26851802","title":"Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.","date":"2016","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/26851802","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32985015","id":"PMC_32985015","title":"Efficacy of BRAF-Inhibitor Therapy in BRAFV600E -Mutated Adult Langerhans Cell Histiocytosis.","date":"2020","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/32985015","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31581557","id":"PMC_31581557","title":"Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31581557","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18473997","id":"PMC_18473997","title":"Therapeutic strategies for targeting BRAF in human cancer.","date":"2007","source":"Reviews on recent clinical trials","url":"https://pubmed.ncbi.nlm.nih.gov/18473997","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26384810","id":"PMC_26384810","title":"Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.","date":"2015","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26384810","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27848137","id":"PMC_27848137","title":"Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.","date":"2016","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27848137","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29033690","id":"PMC_29033690","title":"Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells.","date":"2017","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/29033690","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17956344","id":"PMC_17956344","title":"Mouse models for BRAF-induced cancers.","date":"2007","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17956344","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25961545","id":"PMC_25961545","title":"The role of BRAF in the pathogenesis of thyroid carcinoma.","date":"2015","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/25961545","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21393075","id":"PMC_21393075","title":"Biological challenges of BRAF inhibitor therapy.","date":"2011","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21393075","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29171936","id":"PMC_29171936","title":"BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.","date":"2017","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/29171936","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29061943","id":"PMC_29061943","title":"Comparative Aspects of BRAF Mutations in Canine Cancers.","date":"2015","source":"Veterinary sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29061943","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31453322","id":"PMC_31453322","title":"BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31453322","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25957797","id":"PMC_25957797","title":"BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.","date":"2015","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25957797","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24388103","id":"PMC_24388103","title":"BRAF inhibitors: From the laboratory to clinical trials.","date":"2013","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24388103","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28454577","id":"PMC_28454577","title":"The landscape of BRAF transcript and protein variants in human cancer.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28454577","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29667105","id":"PMC_29667105","title":"The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma.","date":"2018","source":"Targeted oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29667105","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31929109","id":"PMC_31929109","title":"Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31929109","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27097112","id":"PMC_27097112","title":"Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27097112","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28282860","id":"PMC_28282860","title":"Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28282860","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23058743","id":"PMC_23058743","title":"MEK and RAF inhibitors for BRAF-mutated cancers.","date":"2012","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23058743","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35135122","id":"PMC_35135122","title":"BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.","date":"2018","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35135122","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21448135","id":"PMC_21448135","title":"Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21448135","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30482852","id":"PMC_30482852","title":"Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.","date":"2018","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30482852","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33474634","id":"PMC_33474634","title":"Advances in anti-BRAF therapies for lung cancer.","date":"2021","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/33474634","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34298710","id":"PMC_34298710","title":"Autophagy Inhibition in BRAF-Driven Cancers.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34298710","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34831014","id":"PMC_34831014","title":"IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34831014","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29855709","id":"PMC_29855709","title":"Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.","date":"2018","source":"Clinical oral investigations","url":"https://pubmed.ncbi.nlm.nih.gov/29855709","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16964379","id":"PMC_16964379","title":"Regulation of ERK3/MAPK6 expression by BRAF.","date":"2006","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16964379","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35045286","id":"PMC_35045286","title":"Acetylation-dependent regulation of BRAF oncogenic function.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35045286","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26001180","id":"PMC_26001180","title":"BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.","date":"2015","source":"Expert opinion on pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/26001180","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18279546","id":"PMC_18279546","title":"BRAF kinase in melanoma development and progression.","date":"2008","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18279546","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16555627","id":"PMC_16555627","title":"Roles of RAS and BRAF mutations in thyroid carcinogenesis.","date":"2005","source":"Fukushima journal of medical science","url":"https://pubmed.ncbi.nlm.nih.gov/16555627","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25992240","id":"PMC_25992240","title":"BRAF Mutation in Hairy Cell Leukemia.","date":"2014","source":"Oncology reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25992240","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24516336","id":"PMC_24516336","title":"Dabrafenib for treatment of BRAF-mutant melanoma.","date":"2013","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24516336","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31421186","id":"PMC_31421186","title":"Mitochondrial metabolic reprograming via BRAF inhibition ameliorates senescence.","date":"2019","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/31421186","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15035987","id":"PMC_15035987","title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.","date":"2004","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15035987","citation_count":2296,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16618717","id":"PMC_16618717","title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16618717","citation_count":1813,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24024839","id":"PMC_24024839","title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.","date":"2013","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24024839","citation_count":1802,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21107323","id":"PMC_21107323","title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21107323","citation_count":1754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20619739","id":"PMC_20619739","title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.","date":"2010","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20619739","citation_count":1728,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16079850","id":"PMC_16079850","title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16079850","citation_count":1707,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28810144","id":"PMC_28810144","title":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.","date":"2017","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/28810144","citation_count":1665,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16804544","id":"PMC_16804544","title":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.","date":"2006","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16804544","citation_count":1558,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26287849","id":"PMC_26287849","title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.","date":"2015","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26287849","citation_count":1411,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16964243","id":"PMC_16964243","title":"A probability-based approach for high-throughput protein phosphorylation analysis and site localization.","date":"2006","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/16964243","citation_count":1336,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20130576","id":"PMC_20130576","title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20130576","citation_count":1336,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12447372","id":"PMC_12447372","title":"High frequency of BRAF mutations in nevi.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12447372","citation_count":1311,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19001320","id":"PMC_19001320","title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19001320","citation_count":1310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12670889","id":"PMC_12670889","title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12670889","citation_count":1269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20141835","id":"PMC_20141835","title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20141835","citation_count":1221,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26627737","id":"PMC_26627737","title":"High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26627737","citation_count":1200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21107320","id":"PMC_21107320","title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21107320","citation_count":1193,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15302935","id":"PMC_15302935","title":"Large-scale characterization of HeLa cell nuclear phosphoproteins.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15302935","citation_count":1159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12198537","id":"PMC_12198537","title":"Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12198537","citation_count":1032,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20008640","id":"PMC_20008640","title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.","date":"2009","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20008640","citation_count":956,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20519626","id":"PMC_20519626","title":"Recurrent BRAF mutations in Langerhans cell histiocytosis.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20519626","citation_count":902,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12460918","id":"PMC_12460918","title":"BRAF and RAS mutations in human lung cancer and melanoma.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12460918","citation_count":880,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21343559","id":"PMC_21343559","title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.","date":"2011","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21343559","citation_count":860,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14602780","id":"PMC_14602780","title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14602780","citation_count":816,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21274720","id":"PMC_21274720","title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.","date":"2011","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/21274720","citation_count":814,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44785,"output_tokens":4606,"usd":0.101722},"stage2":{"model":"claude-opus-4-6","input_tokens":8077,"output_tokens":3679,"usd":0.19854},"total_usd":0.649586,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59758,"output_tokens":5676,"usd":0.132207},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9469,"output_tokens":3896,"usd":0.217117}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"BRAF somatic missense mutations in the kinase domain, predominantly V600E (V599E), confer elevated serine/threonine kinase activity and transforming capacity in NIH3T3 cells; RAS function is not required for growth of cancer cell lines harboring the V600E mutation, placing BRAF downstream of or parallel to RAS in the MAPK pathway.\",\n      \"method\": \"Genome-wide sequencing of cancer samples, in vitro kinase activity assays, NIH3T3 transformation assay, RAS-independence growth assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original discovery with in vitro kinase assay, transformation assay, and genetic epistasis; foundational paper with >8000 citations\",\n      \"pmids\": [\"12068308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRAF V600E mutation in hairy cell leukemia constitutively activates the RAF-MEK-ERK MAPK pathway, as demonstrated by detection of phosphorylated MEK and ERK in HCL cells; in vitro treatment with the BRAF-specific inhibitor PLX-4720 markedly decreased phospho-ERK and phospho-MEK levels.\",\n      \"method\": \"Western blot for phospho-MEK/ERK, in vitro pharmacological inhibition with PLX-4720 in primary leukemic cells, Sanger sequencing, whole-exome sequencing\",\n      \"journal\": \"The New England Journal of Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical demonstration of pathway activation and pharmacological rescue; replicated across 48 patients\",\n      \"pmids\": [\"21663470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Copper (Cu) is required for oncogenic BRAF V600E signaling and tumorigenesis: decreasing Cu transporter CTR1 levels or mutations in MEK1 that disrupt Cu binding reduced BRAF V600E-driven signaling and tumor growth; a MEK1-MEK5 chimera that phosphorylates ERK1/2 independently of Cu restored tumor growth in Ctr1-deficient cells.\",\n      \"method\": \"Genetic knockdown of CTR1, MEK1 Cu-binding mutants, mouse tumor models, human cell transformation assays, Cu chelation therapy experiments\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal genetic and pharmacological approaches in vitro and in vivo, with mechanistic rescue experiments\",\n      \"pmids\": [\"24717435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Oncogenic BRAF V600E upregulates the ketogenic enzyme HMGCL via the transcription factor Oct-1, leading to increased intracellular acetoacetate levels; acetoacetate selectively enhances binding of BRAF V600E (but not wild-type BRAF) to MEK1, thereby promoting MEK-ERK signaling and tumor growth.\",\n      \"method\": \"Co-immunoprecipitation, metabolite measurement, shRNA knockdown, in vivo xenograft tumor growth assays, transcription factor (Oct-1) ChIP/overexpression studies\",\n      \"journal\": \"Molecular Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical binding assay, genetic manipulation, in vivo rescue, and metabolite measurement with multiple orthogonal methods in single study\",\n      \"pmids\": [\"26145173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRAF V600E drives melanoma cell invasion by inducing phosphorylation of cortactin and the exocyst subunit Exo70 through ERK, thereby regulating actin dynamics and matrix metalloprotease secretion; inhibition of BRAF V600E blocked these invasion-related signaling events.\",\n      \"method\": \"F-actin/cortactin foci assay, extracellular matrix degradation assay, pharmacological BRAF inhibition, genome-wide expression analysis, in vivo mouse melanoma model, patient biopsy IHC\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (functional invasion assay, biochemical phosphorylation, in vivo model) with mechanistic pathway placement\",\n      \"pmids\": [\"27210749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PLX8394 inhibits ERK signaling by specifically disrupting BRAF-containing dimers (BRAF homodimers and BRAF-CRAF heterodimers) but not CRAF homodimers or ARAF-containing dimers; differences in the N-terminal kinase domain amino acid residues of RAF isoforms underlie this differential vulnerability, and PLX8394 inhibits both dimeric BRAF mutants and BRAF V600E monomers.\",\n      \"method\": \"Biochemical RAF dimer disruption assays, ERK signaling assays, mutagenesis of RAF isoform-specific residues, cell-based signaling studies in tumor models\",\n      \"journal\": \"Nature Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic dissection of dimer selectivity with mutagenesis and multiple biochemical assays; strong single-paper evidence\",\n      \"pmids\": [\"30559419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Kinase-inactive BRAF (D631A, corresponding to human D594A) drives lung adenocarcinoma in vivo; kinase-dead BRAF dimerizes with and activates CRAF, and co-expression of Kras G12V with Braf D631A markedly enhances tumor initiation through CRAF kinase activity. Wild-type BRAF kinase activity is required to sustain Kras/Braf-D631A-driven tumors, and its ablation causes oncogenic toxicity through excessive MAPK signaling.\",\n      \"method\": \"Conditional knock-in mouse models, genetic ablation of wild-type Braf allele, MEK inhibitor pharmacological rescue, in vivo lung adenocarcinoma and transdifferentiation phenotype analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rigorous genetic epistasis in vivo with multiple allelic combinations and pharmacological rescue; mechanistic demonstration of CRAF activation by kinase-dead BRAF dimer\",\n      \"pmids\": [\"28783725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Kinase-dead BRAF D594G (class 3 mutation) has higher dimerization potential than wild-type BRAF; the D594G substitution orients the αC-helix toward the active (IN) position and extends the activation loop, priming BRAF D594G as an allosteric activator of CRAF. BRAF/CRAF heterodimers are the most thermodynamically stable RAF dimers and bypass autoinhibitory P-loop phosphorylation.\",\n      \"method\": \"Cell biology, biochemical dimerization assays, molecular dynamics simulations, in vitro kinase assays, co-immunoprecipitation\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — structural modeling combined with multiple biochemical assays and mutagenesis; clear mechanistic explanation of allosteric CRAF activation\",\n      \"pmids\": [\"31929109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ponatinib and the novel inhibitor PHI1 inhibit BRAF dimers by binding to an allosteric site on BRAF that stabilizes a distinct αC-helix conformation; PHI1 shows enhanced inhibition of the second protomer when the first is occupied (positive cooperativity), defining a new class of dimer-selective BRAF inhibitors.\",\n      \"method\": \"Structural analysis, biochemical binding assays, cellular ERK signaling assays, development and testing of PHI1 inhibitor, comparison with FDA-approved drugs\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — structural and biochemical characterization of allosteric site with novel inhibitor design and functional validation\",\n      \"pmids\": [\"32873792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRAF is acetylated at K601 by the acetyltransferase p300, and this modification is reversed by the deacetylase SIRT1; K601 acetylation facilitates BRAF dimerization with RAF proteins and KSR1, promotes melanoma cell proliferation, and contributes to BRAF V600E inhibitor resistance. The oncogenic K601E mutation mimics K601 acetylation to augment kinase activity.\",\n      \"method\": \"Co-immunoprecipitation, acetyltransferase/deacetylase overexpression and knockdown, mutagenesis of K601, melanoma cell proliferation assays, BRAF inhibitor resistance assays\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — identification of writer (p300) and eraser (SIRT1) of acetylation mark, plus functional consequences on dimerization and drug resistance with mutational validation\",\n      \"pmids\": [\"35045286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BRAF V600E signaling upregulates ERK3/MAPK6 expression through MEK1/2; pharmacological inhibition of BRAF or MEK inhibitors that prevent ERK1/2 activation led to rapid ERK3 protein degradation in melanoma cells, demonstrating that ERK3 stability is maintained downstream of the BRAF-MEK pathway.\",\n      \"method\": \"Microarray gene expression profiling with conditionally active BRAF V600E, RNAi-mediated knockdown of BRAF, MEK inhibitor treatment, Western blot for ERK3 protein levels\",\n      \"journal\": \"International Journal of Oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological perturbation with protein-level readout; single lab but two orthogonal methods (RNAi and pharmacological)\",\n      \"pmids\": [\"16964379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRAF V600E-induced oncogene-induced senescence (OIS) requires upregulation of the short TSC22D1 isoform (>100-fold), which acts as a critical effector downstream of C/EBPβ; the short and long TSC22D1 variants have opposing functions in OIS, with the long variant antagonizing senescence; p15(INK4B) and inflammatory factors are regulated by TSC22D1 downstream of BRAF V600E.\",\n      \"method\": \"Gene expression profiling, selective siRNA depletion of TSC22D1 isoforms, overexpression of TSC22D1 variants, in vitro senescence assays in human fibroblasts and melanocytes\",\n      \"journal\": \"The EMBO Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and gain-of-function with specific cellular phenotype; single lab with two orthogonal approaches\",\n      \"pmids\": [\"21448135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRAF inhibitors (αC-helix-OUT compounds) stabilize BRAF V600E in an intermediate inactive conformation that unexpectedly enhances binary RAS:BRAF interactions independently of RAF dimerization in melanoma cells, representing an allosteric communication between the kinase domain and the RAS-binding domain of mutated BRAF.\",\n      \"method\": \"Luciferase-based BRAF conformation biosensors, systematic tracking of full-length BRAF conformations and RAS interactions, comparison of structurally diverse BRAF inhibitors, cell-based signaling studies\",\n      \"journal\": \"Science Advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel biosensor platform with multiple inhibitors; single-lab study with orthogonal mechanistic readouts\",\n      \"pmids\": [\"31453322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Oncogenic BRAF positively regulates expression, phosphorylation, and nuclear localization of ERK5; both ERK5 kinase and transcriptional transactivator activities are enhanced by BRAF V600E. Combined pharmacological inhibition of BRAF V600E and MEK5 is required to decrease nuclear ERK5 and effectively reduce melanoma cell growth.\",\n      \"method\": \"Genetic silencing (siRNA) and pharmacological inhibition of ERK5 and BRAF, xenograft tumor growth assays, ERK5 phosphorylation and localization analysis, colony formation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological loss-of-function with in vivo validation; single-lab study demonstrating BRAF-ERK5 pathway connection\",\n      \"pmids\": [\"29483645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Peptide inhibitors targeting the BRAF dimer interface potently inhibit kinase activity of BRAF homo- and heterodimers including BRAF G469A; disrupting the dimer interface leads to protein degradation of both RAF and MEK, uncovering a scaffolding function of RAF in protecting large MAPK signaling complexes from proteasomal degradation.\",\n      \"method\": \"In silico design of peptide inhibitors, in vitro kinase activity assays against BRAF dimers, cell-based protein degradation assays, combinatorial inhibitor studies with ATP-competitive BRAF inhibitors\",\n      \"journal\": \"ACS Chemical Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assays with designed inhibitors and novel mechanistic finding on RAF scaffolding; single lab\",\n      \"pmids\": [\"31243962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In cells cultured in vitro, BRAF V600E stimulates endogenous MEK and ERK phosphorylation leading to increased cell proliferation, survival, transformation, tumorigenicity, invasion, and vascular development; these hallmarks can be reversed by siRNA to BRAF or by MEK inhibition, establishing BRAF-MEK-ERK as a linear pathway.\",\n      \"method\": \"siRNA knockdown of BRAF, MEK inhibitor treatment, cell proliferation/survival/transformation/tumorigenicity assays, conditional Cre-mediated mouse models\",\n      \"journal\": \"Biochemical Society Transactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological perturbation with multiple cellular phenotype readouts; review consolidating multiple experiments from the lab\",\n      \"pmids\": [\"17956344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Autoantibodies against the BRAF catalytic domain found in rheumatoid arthritis patients stimulate BRAF kinase activity (in contrast to anti-PAD4 antibodies which are inhibitory), demonstrating that extracellular antibody binding to the BRAF catalytic domain can modulate its enzymatic function.\",\n      \"method\": \"Protein array screening of RA patient sera, BRAF kinase activity assay with patient autoantibodies, Sanger sequencing/epitope mapping\",\n      \"journal\": \"Autoimmunity Reviews\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single biochemical assay with no mechanistic follow-up; single-lab study\",\n      \"pmids\": [\"22349616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In response to dual BRAF/MEK inhibitor treatment, transcriptional upregulation of FGF1 results in autocrine activation of FGFR, which reactivates ERK and drives adaptive resistance; FGFR inhibition overcomes resistance in cell lines and patient-derived xenograft models.\",\n      \"method\": \"Generation of dual BRAFi/MEKi-resistant cell lines, pharmacologic synthetic lethal screening, transcriptional profiling, PDX models, serum FGF1 clinical correlation\",\n      \"journal\": \"Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway placement via pharmacological rescue in multiple models including PDX; single-lab study\",\n      \"pmids\": [\"31515463\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRAF is a RAS-regulated cytoplasmic serine/threonine kinase that, upon activation (most commonly by the V600E mutation), functions as a monomer or dimer to phosphorylate and activate MEK1/2, which in turn activates ERK1/2 to drive proliferation, survival, and invasion; kinase-dead BRAF variants allosterically activate CRAF through dimerization; BRAF activity is modulated by copper-dependent MEK1 interactions, acetylation at K601 by p300/SIRT1, and dimer-interface-mediated scaffolding of the MAPK complex, while oncogenic BRAF V600E additionally rewires metabolism through the Oct-1–HMGCL–acetoacetate axis to selectively enhance its own binding to MEK1.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"BRAF somatic missense mutations occur in 66% of malignant melanomas and at lower frequency across many human cancers; all mutations are within the kinase domain, with V599E (V600E) accounting for ~80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. RAS function is not required for growth of cancer cell lines with the V600E mutation.\",\n      \"method\": \"Genome-wide sequencing screen, in vitro kinase assays, NIH3T3 transformation assay, cell line growth assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original discovery with kinase assays and transformation assays, massively replicated\",\n      \"pmids\": [\"12068308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Crystal structures of wild-type and oncogenic V599E BRAF kinase domains reveal that the activation segment is held in an inactive conformation by association with the P-loop. Most oncogenic mutations disrupt this inhibitory interaction, converting BRAF to its active conformation. High-activity mutants signal to ERK by directly phosphorylating MEK, whereas kinase-impaired mutants stimulate MEK by activating endogenous C-RAF, possibly via allosteric or transphosphorylation mechanisms.\",\n      \"method\": \"X-ray crystallography of BRAF kinase domain (WT and V599E), in vitro kinase assays of 22 BRAF mutants, ERK signaling assays in cells\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure combined with functional mutagenesis and kinase assays, foundational mechanism paper\",\n      \"pmids\": [\"15035987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BRAF(V600E) expression in primary human melanocytes induces cell cycle arrest with hallmarks of oncogene-induced senescence (OIS), including p16(INK4a) induction and senescence-associated beta-galactosidase activity. Congenital naevi are invariably positive for SA-beta-Gal in vivo, demonstrating that BRAF(V600E) drives senescence rather than proliferation in the benign lesion context.\",\n      \"method\": \"Retroviral expression of BRAF(V600E) in human melanocytes, SA-beta-Gal assay, p16(INK4a) immunostaining, in vivo nevi analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean loss/gain-of-function with defined cellular phenotype, validated in vivo, replicated by subsequent studies\",\n      \"pmids\": [\"16079850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ATP-competitive RAF inhibitors have two opposing mechanisms depending on cellular context: in BRAF(V600E) tumors they block MAPK signaling, but in KRAS-mutant or RAS/RAF wild-type tumors they activate the RAF-MEK-ERK pathway by inducing wild-type RAF dimerization, membrane localization, and interaction with RAS-GTP—events linked to conformational effects on the RAF kinase domain independent of kinase inhibition.\",\n      \"method\": \"Cellular signaling assays in multiple tumor cell lines and xenograft models, biochemical studies of RAF dimerization, membrane fractionation, co-immunoprecipitation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, replicated across labs, mechanistic basis for paradoxical activation\",\n      \"pmids\": [\"20130576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Kinase-dead BRAF, when present with oncogenic RAS, drives MEK-ERK signaling and tumor progression through CRAF. BRAF-selective drugs promote RAS-dependent BRAF binding to CRAF and CRAF activation specifically when oncogenic RAS is present. Kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.\",\n      \"method\": \"Genetic mouse model (kinase-dead Braf + oncogenic Ras), CRAF co-immunoprecipitation, MEK-ERK phosphorylation assays, siRNA knockdown, mouse melanoma model\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo mouse model plus biochemical mechanism, replicated concept across multiple studies\",\n      \"pmids\": [\"20141835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Copper (Cu) is required for oncogenic BRAF(V600E) signaling and tumorigenesis. CTR1 (Cu transporter 1) deficiency or MEK1 mutations disrupting Cu binding decreased BRAF(V600E)-driven signaling and tumor growth. A MEK1-MEK5 chimera that phosphorylated ERK1/2 independently of Cu, or active ERK2, restored tumor growth in Ctr1-deficient cells. Cu chelators reduced BRAF(V600E)-driven tumor growth.\",\n      \"method\": \"CTR1 knockdown/knockout in mouse and human cells, MEK1 Cu-binding mutants, rescue experiments, tumor xenograft/mouse models, Cu chelation treatment\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacologic approaches, in vivo validation\",\n      \"pmids\": [\"24717435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Oncogenic BRAF V600E upregulates the ketogenic enzyme HMGCL through octamer transcription factor Oct-1, leading to increased intracellular acetoacetate. Acetoacetate selectively enhances binding of BRAF(V600E) but not wild-type BRAF to MEK1, promoting MEK-ERK signaling activation in a V600E-specific manner. HMGCL suppression specifically attenuates proliferation and tumor growth in BRAF(V600E)-expressing cells.\",\n      \"method\": \"Metabolomics, co-immunoprecipitation of BRAF(V600E)/BRAF-WT with MEK1, HMGCL knockdown/overexpression, Oct-1 transcription factor assays, xenograft tumor models\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical binding assay distinguishing V600E vs WT, multiple orthogonal methods, in vivo validation\",\n      \"pmids\": [\"26145173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRAF(V600E) drives melanoma cell invasion by inducing phosphorylation of cortactin and the exocyst subunit Exo70 through ERK, which regulates actin dynamics (F-actin and cortactin foci/invadopodia) and matrix metalloprotease secretion, respectively. BRAF(V600E) inhibition blocks invasion, decreases cortactin foci in murine melanoma models and patient biopsies, and downregulates invadopodia-related genes.\",\n      \"method\": \"F-actin/cortactin imaging, matrix degradation assays, ERK substrate phosphorylation analysis, BRAF(V600E) inhibitor treatment, murine model and patient biopsies, genome-wide expression analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway placement with defined substrates, in vitro and in vivo validation\",\n      \"pmids\": [\"27210749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Kinase-inactive BRAF(D631A) (corresponding to human BRAF(D594A)) acts as an oncogenic initiating event in lung adenocarcinoma in vivo. Co-expression with Kras(G12V) enhances tumor initiation via Craf kinase activity. Wild-type Braf kinase is required to sustain these tumors; its ablation causes excessive MAPK signaling leading to oncogenic toxicity, which can be reversed by MEK inhibition. Loss of wild-type Braf also triggers transdifferentiation of club cells.\",\n      \"method\": \"Conditional knock-in mouse models, Cre-mediated activation, genetic Braf ablation, pharmacological MEK inhibition, histopathological analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — sophisticated in vivo mouse genetics with multiple genetic interventions and defined phenotypes\",\n      \"pmids\": [\"28783725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PLX8394 inhibits ERK signaling by specifically disrupting BRAF-containing dimers (BRAF homodimers and BRAF-CRAF heterodimers) but not CRAF homodimers or ARAF-containing dimers. Differences in the N-terminal portion of the kinase domain among RAF isoforms determine this differential vulnerability. PLX8394 selectively inhibits ERK signaling in tumors driven by dimeric BRAF mutants, including fusions, splice variants, and V600 monomers, but spares CRAF-homodimer-driven signaling in normal cells.\",\n      \"method\": \"Cell-based ERK signaling assays, selective dimer disruption biochemistry, comparisons across RAF isoforms, tumor cell line panels with varied BRAF mutations\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of dimer-specific signaling with isoform mutagenesis and pharmacological validation\",\n      \"pmids\": [\"30559419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRAF inhibitors stabilize an intermediate, inactive kinase conformation of BRAF(V600E) that enhances binary RAS:RAF interactions independently of RAF dimerization in melanoma cells. This represents an allosteric effect of drug-driven intramolecular communication between the kinase and RAS-binding domains of mutated BRAF, which may promote paradoxical kinase activation and drug resistance.\",\n      \"method\": \"Luciferase-based BRAF conformation biosensors, RAS:RAF interaction assays, melanoma cell RAF dimerization studies, structurally diverse inhibitor panel\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel biosensor approach with pharmacological validation, single lab\",\n      \"pmids\": [\"31453322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRAF(D594G), a kinase-dead class 3 mutant, has higher dimerization potential than wild-type BRAF. Molecular dynamics simulations show the D594G substitution orients the αC-helix toward the IN position and extends the activation loop, shifting equilibrium toward the active dimeric conformation, priming BRAF(D594G) as an allosteric activator of CRAF. BRAF/CRAF heterodimers are the most thermodynamically stable RAF dimers. BRAF(D594G):CRAF heterodimers bypass autoinhibitory P-loop phosphorylation.\",\n      \"method\": \"Cell biology, biochemical dimerization assays, molecular dynamics simulations, P-loop phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical plus computational approach, single lab\",\n      \"pmids\": [\"31929109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ponatinib inhibits BRAF monomers and dimers by binding to an allosteric site that stabilizes a distinct αC-helix conformation. Using structural insights from ponatinib, a BRAF inhibitor PHI1 was developed that selectively inhibits BRAF dimers, with enhanced inhibition of the second protomer when the first is occupied (positively cooperative dimer inhibition), defining a novel class of dimer-selective inhibitors.\",\n      \"method\": \"Structural analysis, cell-based BRAF dimer selectivity assays, medicinal chemistry/compound development, ERK signaling assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structural and functional dimer inhibition data, single lab\",\n      \"pmids\": [\"32873792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The acetyltransferase p300 activates BRAF kinase by promoting BRAF K601 acetylation, a process antagonized by the deacetylase SIRT1. K601 acetylation facilitates BRAF dimerization with RAF proteins and KSR1, promotes melanoma cell proliferation, and contributes to BRAF(V600E) inhibitor resistance. The oncogenic K601E mutation mimics K601 acetylation to augment BRAF kinase activity.\",\n      \"method\": \"Acetylation assays, p300/SIRT1 co-immunoprecipitation, BRAF dimerization assays, cell proliferation and drug resistance assays, K601E mutation analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — identified writer (p300) and eraser (SIRT1) of a PTM with functional validation, single lab\",\n      \"pmids\": [\"35045286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Peptide inhibitors targeting the BRAF dimer interface potently inhibit kinase activity of BRAF homo- and heterodimers, including oncogenic BRAF(G469A). Targeting the dimer interface leads to protein degradation of both RAF and MEK, revealing a novel scaffolding function of RAF in protecting large MAPK signaling complexes from proteasomal degradation.\",\n      \"method\": \"In silico peptide design, in vitro kinase assays on BRAF homo/heterodimers, protein stability assays, RAF/MEK degradation studies in cancer cells\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro kinase assays plus cellular scaffolding function discovery, single lab\",\n      \"pmids\": [\"31243962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TSC22D1 short transcript is upregulated >100-fold in BRAF(E600)-induced senescence in human fibroblasts and melanocytes, while the large TSC22D1 protein variant is suppressed by proteasomal degradation. Selective depletion of the short form, or overexpression of the large form, abrogates OIS and suppresses inflammatory factors and p15(INK4B). TSC22D1 is a critical effector of C/EBPβ in BRAF(V600E)-driven OIS.\",\n      \"method\": \"Gene expression profiling, shRNA knockdown, overexpression experiments, senescence assays (SA-beta-Gal, p16/p15 staining) in human fibroblasts and melanocytes\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown and overexpression with defined senescence phenotypes, single lab\",\n      \"pmids\": [\"21448135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Oncogenic BRAF and AXL drive loss of RIPK3 expression in cancer cells, leading to resistance to necroptosis. Inhibition of BRAF (or AXL) rescues RIPK3 expression and restores necroptosis sensitivity, placing BRAF as an oncogenic driver that suppresses the RIPK1-RIPK3-MLKL necroptosis pathway.\",\n      \"method\": \"Genome-wide bioinformatics screen of 941 cancer cell lines, BRAF/AXL inhibitor treatment, RIPK3 expression rescue assays, necroptosis sensitivity assays\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — large-scale screen with pharmacological validation, single lab\",\n      \"pmids\": [\"30157175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BRAF(V600E) signaling through MEK1/2 upregulates ERK3/MAPK6 expression. ERK3 protein is unstable and rapidly degraded upon pharmacological BRAF inhibition. In melanoma cells, RNAi knockdown of BRAF or MEK inhibitor treatment reduces ERK3 levels, demonstrating ERK3 as a downstream transcriptional target of the BRAF-MEK axis.\",\n      \"method\": \"Conditionally active BRAF(V600E) expression system, microarray expression profiling, pharmacological BRAF/MEK inhibition, RNAi knockdown, protein stability assays\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional expression system plus RNAi and inhibitor validation, single lab\",\n      \"pmids\": [\"16964379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ERK5 expression, phosphorylation, and nuclear localization are positively regulated by oncogenic BRAF(V600E). Both ERK5 kinase and transcriptional transactivator activities are enhanced by BRAF. Nuclear ERK5 is critical for cell proliferation in melanoma, and combined pharmacological inhibition of BRAF(V600E) and MEK5 is required to decrease nuclear ERK5 and achieve greater anti-tumor efficacy.\",\n      \"method\": \"ERK5 knockdown, pharmacological inhibition of BRAF(V600E)/MEK5/ERK5, subcellular fractionation/localization assays, colony formation, xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitors and genetic knockdown with defined nuclear localization phenotype, single lab\",\n      \"pmids\": [\"29483645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Acquired resistance to PLX4032 (vemurafenib) in BRAF(V600E) melanoma develops through mutually exclusive PDGFRβ upregulation or NRAS mutations, but not through secondary mutations in BRAF(V600E). PDGFRβ-upregulated cells maintain low activated RAS and do not reactivate MAPK upon PLX4032 treatment, while NRAS-mutant resistant cells show significant MAPK reactivation and MEK inhibitor sensitivity.\",\n      \"method\": \"PLX4032-resistant subline derivation, patient biopsy analysis, PDGFRβ/NRAS knockdown and overexpression, MAPK pathway signaling assays, patient-derived short-term cultures\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clinical samples plus cell line mechanistic studies, validated in patient biopsies, independently replicated concept\",\n      \"pmids\": [\"21107323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MAP3K8 (COT/Tpl2) drives resistance to RAF inhibition in BRAF(V600E) melanoma by activating ERK through MEK-dependent mechanisms that do not require RAF signaling. COT expression is associated with de novo and acquired resistance in BRAF(V600E) cell lines and patient-derived relapsing tumor tissue.\",\n      \"method\": \"Kinase ORF expression screen (~600 kinases), patient biopsy analysis, MEK/ERK signaling assays, COT inhibition studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large-scale functional screen validated in patient samples and cell lines\",\n      \"pmids\": [\"21107320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In response to dual BRAF/MEK inhibitor treatment, transcriptional upregulation of FGF1 results in autocrine activation of FGFR, which reactivates ERK as an adaptive resistance mechanism. FGFR inhibition overcomes resistance to dual BRAF/MEK inhibitors in cell lines and patient-derived xenograft models.\",\n      \"method\": \"Drug-resistant cell line generation, pharmacologic synthetic lethal screen, FGF1 expression analysis, FGFR inhibition rescue experiments, PDX models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis with PDX validation, single lab\",\n      \"pmids\": [\"31515463\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRAF is a RAS-regulated serine/threonine kinase that, in its active conformation (disrupted by oncogenic mutations such as V600E), directly phosphorylates MEK to activate the ERK MAPK pathway; V600E functions as a constitutively active monomer while kinase-impaired class 3 mutants signal allosterically through CRAF dimers, and wild-type BRAF activity is modulated by RAS-GTP-driven dimerization, copper-dependent MEK interactions, acetylation at K601 by p300 (reversed by SIRT1), and inhibitor-induced conformational changes that can paradoxically activate signaling in RAS-mutant cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BRAF is a RAS-regulated serine/threonine kinase that functions as the principal activator of the MEK–ERK MAPK signaling cascade, controlling cell proliferation, survival, invasion, and senescence. Oncogenic gain-of-function mutations, most notably V600E, confer constitutive, RAS-independent kinase activity that directly phosphorylates MEK1/2 to drive ERK activation across diverse cancers including melanoma and hairy cell leukemia [PMID:12068308, PMID:21663470]. Kinase-dead BRAF variants (e.g., D594A/G) allosterically activate CRAF through obligate heterodimerization, with the dimer interface also serving a scaffolding function that protects the assembled MAPK complex from proteasomal degradation [PMID:28783725, PMID:31929109, PMID:31243962]. BRAF activity is further tuned by acetylation at K601 (written by p300, erased by SIRT1) which promotes RAF dimerization and inhibitor resistance, and by copper-dependent MEK1 interactions and a V600E-specific metabolic feedforward loop operating through the Oct-1–HMGCL–acetoacetate axis [PMID:35045286, PMID:24717435, PMID:26145173].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"The discovery that somatic BRAF V600E mutations confer constitutive kinase activity and RAS-independent transformation established BRAF as a direct oncogenic driver and positioned it as a critical node between RAS and MEK in the MAPK pathway.\",\n      \"evidence\": \"Genome-wide cancer sequencing, in vitro kinase assays, and NIH3T3 transformation/RAS-independence growth assays\",\n      \"pmids\": [\"12068308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for enhanced V600E kinase activity not resolved\", \"No in vivo genetic model at this stage\", \"Role of BRAF dimerization not yet addressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Systematic perturbation confirmed that BRAF V600E signals through a linear BRAF→MEK→ERK cascade to control proliferation, survival, transformation, invasion, and vascular development, solidifying the pathway architecture.\",\n      \"evidence\": \"siRNA knockdown and MEK inhibitor treatment in multiple cellular assays and conditional mouse models\",\n      \"pmids\": [\"17956344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effectors beyond ERK1/2 not delineated\", \"Contribution of non-ERK1/2 branches not excluded\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstration that V600E constitutively activates MEK/ERK in hairy cell leukemia—and that BRAF-specific inhibition abrogates this—extended the oncogenic mechanism beyond melanoma and validated BRAF as a therapeutic target in hematologic malignancy.\",\n      \"evidence\": \"Phospho-MEK/ERK western blots and PLX-4720 inhibitor treatment in primary HCL cells from 48 patients\",\n      \"pmids\": [\"21663470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of V600E selectivity in HCL lineage not established\", \"Long-term resistance mechanisms not studied\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"BRAF V600E was found to trigger oncogene-induced senescence through C/EBPβ-dependent upregulation of short TSC22D1, revealing a tumor-suppressive brake on BRAF-driven transformation.\",\n      \"evidence\": \"Isoform-selective siRNA and overexpression of TSC22D1 variants in human fibroblasts and melanocytes with senescence readouts\",\n      \"pmids\": [\"21448135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of TSC22D1-mediated OIS not tested\", \"Whether other RAF mutations trigger the same senescence program is unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of copper as an essential cofactor for BRAF V600E signaling—acting through Cu-dependent MEK1 binding—revealed an unexpected metabolic dependency of oncogenic BRAF.\",\n      \"evidence\": \"CTR1 knockdown, MEK1 Cu-binding mutants, Cu chelation in mouse tumor models, and rescue with Cu-independent MEK1–MEK5 chimera\",\n      \"pmids\": [\"24717435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cu-binding site on MEK1 not structurally resolved at atomic level\", \"Whether wild-type BRAF signaling shares the same Cu dependency is unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery of a metabolic feedforward loop—V600E upregulates HMGCL via Oct-1, and the resulting acetoacetate selectively enhances V600E–MEK1 binding—established a mutation-specific metabolic amplifier of MAPK signaling.\",\n      \"evidence\": \"Co-immunoprecipitation, metabolite quantification, shRNA knockdown, and in vivo xenograft rescue\",\n      \"pmids\": [\"26145173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for acetoacetate selectivity toward V600E over wild-type BRAF not determined\", \"Whether other ketone bodies similarly modulate BRAF is unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"BRAF V600E was shown to drive melanoma cell invasion via ERK-mediated phosphorylation of cortactin and exocyst subunit Exo70, connecting BRAF to actin remodeling and MMP secretion.\",\n      \"evidence\": \"F-actin/cortactin foci assays, matrix degradation assays, BRAF inhibition, and in vivo mouse melanoma model\",\n      \"pmids\": [\"27210749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase–substrate relationship between ERK and Exo70 not demonstrated with purified proteins\", \"Contribution of invasion program to metastasis in patients not causally tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"In vivo genetic studies established that kinase-dead BRAF drives tumorigenesis by dimerizing with and allosterically activating CRAF, and that the wild-type BRAF allele paradoxically restrains excessive MAPK output in this context.\",\n      \"evidence\": \"Conditional knock-in mouse models with Braf D631A, genetic ablation of the wild-type Braf allele, and MEK inhibitor rescue in lung adenocarcinoma\",\n      \"pmids\": [\"28783725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise stoichiometry and kinetics of kinase-dead BRAF/CRAF dimer in vivo not measured\", \"Whether other kinase-dead mutations behave identically is untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"BRAF V600E was found to regulate ERK5 expression, phosphorylation, and nuclear translocation, identifying a parallel MAPK branch that contributes to melanoma growth and requires combined BRAF/MEK5 inhibition.\",\n      \"evidence\": \"siRNA and pharmacological inhibition of ERK5 and BRAF, ERK5 localization analysis, and xenograft models\",\n      \"pmids\": [\"29483645\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BRAF directly phosphorylates MEK5 or acts indirectly is unresolved\", \"Relative contribution of ERK5 vs ERK1/2 to proliferation not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"PLX8394 was shown to selectively disrupt BRAF-containing dimers (but not CRAF or ARAF dimers), revealing that isoform-specific N-terminal kinase domain residues dictate dimer vulnerability and opening a new pharmacological strategy against dimeric BRAF mutants.\",\n      \"evidence\": \"RAF dimer disruption assays, mutagenesis of isoform-specific residues, and cell-based ERK signaling studies\",\n      \"pmids\": [\"30559419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical efficacy of dimer-selective inhibitors not yet demonstrated\", \"Structural basis for isoform selectivity at atomic resolution incomplete\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Peptide inhibitors targeting the BRAF dimer interface uncovered a scaffolding function of RAF dimers: interface disruption destabilizes both RAF and MEK proteins via proteasomal degradation, showing that dimers protect the assembled MAPK signaling complex.\",\n      \"evidence\": \"In silico-designed peptide inhibitors, in vitro kinase assays, and cell-based protein degradation assays\",\n      \"pmids\": [\"31243962\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Scaffolding function not validated in vivo\", \"Identity of the E3 ubiquitin ligase responsible for RAF/MEK degradation not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"αC-helix-OUT BRAF inhibitors were found to paradoxically stabilize an intermediate inactive BRAF conformation that enhances RAS–BRAF binding independently of dimerization, revealing allosteric communication between the kinase and RAS-binding domains.\",\n      \"evidence\": \"Luciferase-based BRAF conformation biosensors and systematic comparison of diverse BRAF inhibitors in melanoma cells\",\n      \"pmids\": [\"31453322\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of allosteric coupling between kinase domain and RBD not resolved\", \"Functional consequence of enhanced RAS–BRAF interaction during treatment not fully characterized\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Molecular dynamics and biochemical analyses of kinase-dead BRAF D594G showed that the substitution positions the αC-helix in an active (IN) conformation and extends the activation loop, explaining how class 3 BRAF mutations allosterically prime CRAF activation in heterodimers.\",\n      \"evidence\": \"Molecular dynamics simulations, co-immunoprecipitation, dimerization assays, and in vitro kinase assays\",\n      \"pmids\": [\"31929109\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of BRAF D594G/CRAF heterodimer not available\", \"Whether all class 3 mutations share this αC-helix mechanism is assumed but not individually tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of an allosteric dimer site on BRAF bound by ponatinib and PHI1—with positive cooperativity for the second protomer—defined a pharmacologically exploitable mechanism for selective dimer inhibition distinct from ATP-competitive approaches.\",\n      \"evidence\": \"Structural analysis, biochemical binding assays, and cellular ERK signaling assays with novel inhibitor PHI1\",\n      \"pmids\": [\"32873792\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy and selectivity of PHI1 not demonstrated\", \"Whether cooperativity generalizes to all dimer-mutant BRAF forms is untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that p300 acetylates BRAF at K601 and SIRT1 deacetylates it—with acetylation promoting dimerization with RAF/KSR1 and contributing to V600E inhibitor resistance—added a reversible post-translational layer to BRAF dimer regulation and explained the oncogenicity of the K601E substitution.\",\n      \"evidence\": \"Co-immunoprecipitation, acetyltransferase/deacetylase overexpression and knockdown, K601 mutagenesis, melanoma proliferation and drug resistance assays\",\n      \"pmids\": [\"35045286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetylation stoichiometry in tumors not quantified\", \"Whether other acetylation sites on BRAF contribute to regulation is unknown\", \"Role of SIRT1 in BRAF regulation in vivo not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Despite extensive characterization of BRAF dimerization and its pharmacological vulnerabilities, no high-resolution structure of a full-length, autoinhibited BRAF–CRAF heterodimer in complex with MEK exists, and the precise mechanism by which upstream signals coordinate the transition from autoinhibited monomer to active dimer in physiological (non-mutant) BRAF signaling remains incompletely defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length BRAF–CRAF heterodimer structure not solved\", \"Quantitative kinetics of RAS-dependent BRAF activation in living cells not measured\", \"Relative contributions of BRAF homodimers vs BRAF–CRAF heterodimers to normal signaling not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 6, 7, 9, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 7, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1, 5, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 5, 6, 7, 8, 12, 15]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 11, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 3, 4, 6, 13, 17]}\n    ],\n    \"complexes\": [\n      \"BRAF-CRAF heterodimer\",\n      \"BRAF homodimer\",\n      \"BRAF-KSR1 complex\"\n    ],\n    \"partners\": [\n      \"CRAF\",\n      \"MEK1\",\n      \"MEK2\",\n      \"KSR1\",\n      \"KRAS\",\n      \"EP300\",\n      \"SIRT1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"BRAF is a RAS-regulated serine/threonine kinase that serves as the principal activator of the MEK–ERK MAPK cascade, governing cell proliferation, differentiation, senescence, and survival. Its kinase domain adopts an autoinhibited conformation in which the activation segment associates with the P-loop; oncogenic mutations—most commonly V600E—disrupt this interaction, yielding a constitutively active monomer that directly phosphorylates MEK, whereas kinase-impaired (class 3) mutants such as D594G signal allosterically through RAS-dependent BRAF–CRAF heterodimers [PMID:15035987, PMID:31929109]. BRAF activity is further modulated by p300-mediated acetylation at K601 (reversed by SIRT1), which promotes RAF dimerization and drug resistance, and by copper availability through CTR1, which is required for productive MEK phosphorylation [PMID:35045286, PMID:24717435]. Somatic BRAF mutations—found in ~66% of melanomas and many other cancers—drive tumorigenesis but also trigger oncogene-induced senescence in primary melanocytes; acquired resistance to BRAF inhibitors arises through NRAS mutation, PDGFRβ upregulation, COT/MAP3K8 expression, or FGF1–FGFR reactivation, while first-generation ATP-competitive RAF inhibitors paradoxically activate MAPK in RAS-mutant cells by promoting wild-type RAF dimerization [PMID:12068308, PMID:16079850, PMID:20130576, PMID:21107323].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"The discovery that BRAF is the most frequently mutated kinase in melanoma established it as a direct oncogenic driver, with V600E accounting for ~80% of mutations and conferring constitutive kinase activity independent of RAS.\",\n      \"evidence\": \"Genome-wide cancer mutation screen, in vitro kinase assays, NIH3T3 transformation assay across hundreds of tumor samples\",\n      \"pmids\": [\"12068308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of how V600E activates the kinase was unknown\", \"Whether mutant BRAF could be therapeutically targeted was untested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Crystallography of the BRAF kinase domain revealed that the P-loop–activation segment interaction maintains autoinhibition and that oncogenic mutations disrupt this interaction; critically, kinase-impaired mutants were shown to activate ERK through CRAF rather than directly phosphorylating MEK, establishing two mechanistically distinct classes of BRAF oncogenic mutations.\",\n      \"evidence\": \"X-ray crystallography of WT and V599E BRAF kinase domains, in vitro kinase assays of 22 mutants, cellular ERK signaling assays\",\n      \"pmids\": [\"15035987\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise mechanism by which kinase-dead BRAF activates CRAF (allosteric vs. transphosphorylation) was unresolved\", \"No co-structure of BRAF dimers available\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that BRAF(V600E) triggers oncogene-induced senescence rather than proliferation in primary melanocytes resolved the paradox of why BRAF mutations are found in benign nevi, establishing a tumor-suppressive barrier that must be overcome for melanoma progression.\",\n      \"evidence\": \"Retroviral V600E expression in human melanocytes, SA-β-Gal and p16(INK4a) staining, in vivo nevi analysis\",\n      \"pmids\": [\"16079850\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which cooperating lesions allow escape from OIS was not defined\", \"Molecular effectors downstream of BRAF in the senescence program were incompletely mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Three concurrent studies resolved how RAF inhibitors paradoxically activate ERK in RAS-mutant cells (via drug-induced wild-type RAF dimerization), how kinase-dead BRAF cooperates with oncogenic RAS through CRAF activation in vivo, and how clinical resistance to vemurafenib arises through PDGFRβ upregulation or NRAS mutations—collectively defining the dimerization-dependent and bypass mechanisms that limit monotherapy efficacy.\",\n      \"evidence\": \"Cellular signaling across tumor line panels, co-immunoprecipitation, membrane fractionation, conditional mouse models (kinase-dead Braf + oncogenic Ras), patient biopsies, resistant subline derivation\",\n      \"pmids\": [\"20130576\", \"20141835\", \"21107323\", \"21107320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dimer-breaking compounds could overcome paradoxical activation was untested\", \"Full landscape of resistance mechanisms in patients was incomplete\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of TSC22D1 as a critical effector of C/EBPβ in BRAF(V600E)-driven OIS provided the first molecular link between the BRAF-ERK pathway and the transcriptional senescence program in melanocytes.\",\n      \"evidence\": \"Gene expression profiling, shRNA knockdown and overexpression in human fibroblasts/melanocytes, SA-β-Gal and p15 assays\",\n      \"pmids\": [\"21448135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TSC22D1 is required for OIS in vivo was not tested\", \"Other senescence effectors downstream of BRAF were not systematically mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing that copper, via CTR1, is required for BRAF(V600E)-driven MEK phosphorylation and tumorigenesis introduced a metabolic cofactor dependency into the MAPK signaling model and provided a rationale for copper chelation as a therapeutic strategy.\",\n      \"evidence\": \"CTR1 knockout/knockdown, MEK1 Cu-binding mutants, rescue experiments, tumor xenograft and mouse models, Cu chelation\",\n      \"pmids\": [\"24717435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural evidence of Cu binding to MEK in the BRAF–MEK complex was lacking\", \"Clinical utility of Cu chelation was not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that BRAF(V600E) upregulates the ketogenic enzyme HMGCL, leading to acetoacetate accumulation that selectively enhances V600E–MEK1 binding, revealed an unexpected metabolic feed-forward loop specific to the oncogenic mutant.\",\n      \"evidence\": \"Metabolomics, co-immunoprecipitation of BRAF variants with MEK1, HMGCL knockdown/overexpression, xenograft models\",\n      \"pmids\": [\"26145173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of acetoacetate-enhanced V600E–MEK1 binding was unknown\", \"Relevance beyond melanoma not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapping BRAF(V600E)-driven invasion to ERK-dependent phosphorylation of cortactin (actin remodeling/invadopodia) and Exo70 (MMP secretion) extended the functional repertoire of oncogenic BRAF from proliferation and senescence to metastatic cell behavior.\",\n      \"evidence\": \"F-actin/cortactin imaging, matrix degradation assays, BRAF inhibitor treatment in murine models and patient biopsies\",\n      \"pmids\": [\"27210749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether these effectors are relevant in non-melanoma BRAF-driven cancers was not addressed\", \"Direct ERK phosphorylation sites on cortactin and Exo70 were not fully mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"In vivo demonstration that kinase-dead BRAF(D594A) initiates lung adenocarcinoma and that wild-type BRAF is required to buffer MAPK output—its loss causing lethal ERK hyperactivation—established that BRAF functions both as an allosteric activator and a homeostatic regulator of MAPK flux.\",\n      \"evidence\": \"Conditional knock-in mouse models with genetic Braf ablation and pharmacological MEK inhibition\",\n      \"pmids\": [\"28783725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this buffering role applies in tissues other than lung was not tested\", \"Mechanism by which wild-type BRAF limits CRAF output was not structurally resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Concurrent studies showed that oncogenic BRAF suppresses necroptosis by silencing RIPK3 and upregulates nuclear ERK5 transcriptional activity, broadening the downstream effector landscape beyond canonical ERK1/2; additionally, PLX8394 was shown to selectively disrupt BRAF-containing dimers without affecting CRAF homodimers, providing a pharmacological proof-of-concept for dimer-selective RAF inhibition.\",\n      \"evidence\": \"Genome-wide screen of 941 cancer cell lines for RIPK3 loss, BRAF/AXL inhibitor rescue of necroptosis; ERK5 subcellular fractionation and combined BRAF/MEK5 inhibition; PLX8394 dimer disruption biochemistry across RAF isoforms\",\n      \"pmids\": [\"30157175\", \"29483645\", \"30559419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RIPK3 silencing is epigenetic or transcriptional was not determined\", \"ERK5-specific transcriptional targets downstream of BRAF were not identified\", \"PLX8394 clinical efficacy in dimer-driven tumors was untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Three advances refined the mechanistic picture: BRAF inhibitors were shown to stabilize an intermediate kinase conformation that allosterically enhances RAS–RAF binding independently of dimerization; peptide-mediated disruption of the BRAF dimer interface triggered proteasomal degradation of both RAF and MEK, revealing a scaffolding function; and FGF1–FGFR autocrine reactivation was identified as an adaptive resistance mechanism to combined BRAF/MEK inhibition.\",\n      \"evidence\": \"Luciferase-based BRAF conformation biosensors in melanoma cells; in silico peptide design with in vitro kinase and protein stability assays; drug-resistant cell line generation with FGFR inhibition in PDX models\",\n      \"pmids\": [\"31453322\", \"31243962\", \"31515463\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Allosteric RAS–RAF enhancement awaits structural resolution\", \"Scaffolding function of RAF dimers not confirmed in vivo\", \"Clinical validation of FGFR co-inhibition in BRAF-mutant patients was lacking\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Molecular dynamics and biochemical studies of class 3 mutant BRAF(D594G) demonstrated that the mutation shifts αC-helix orientation toward the active state, increasing dimerization potential and priming allosteric CRAF activation while bypassing P-loop autoinhibition; separately, a cooperative dimer-selective BRAF inhibitor (PHI1) was developed using structural insights from ponatinib, defining a new pharmacological class.\",\n      \"evidence\": \"MD simulations, biochemical dimerization/P-loop phosphorylation assays; structural analysis and medicinal chemistry with cell-based ERK assays\",\n      \"pmids\": [\"31929109\", \"32873792\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental structure of D594G dimer was obtained\", \"PHI1 not tested in vivo or in clinical samples\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of p300-mediated acetylation at K601 (reversed by SIRT1) as a direct activating modification of BRAF that promotes dimerization with RAF/KSR1 and confers BRAF inhibitor resistance added a post-translational regulatory layer to the dimerization-dependent activation model and explained the oncogenic K601E mutation as an acetylation mimic.\",\n      \"evidence\": \"Acetylation assays, p300/SIRT1 co-immunoprecipitation, BRAF dimerization and drug resistance assays, K601E mutation analysis\",\n      \"pmids\": [\"35045286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of K601 acetylation in tumor progression not tested\", \"Whether other acetyltransferases contribute is unknown\", \"Structural basis of acetylation-enhanced dimerization not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full structural basis of RAS-driven BRAF dimerization at the membrane, the determinants of tissue-specific responses to kinase-dead BRAF alleles, and whether dimer-selective or cooperative RAF inhibitors can achieve durable clinical responses without paradoxical activation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length BRAF structure in complex with RAS at the membrane\", \"Tissue-specific determinants of kinase-dead BRAF oncogenicity are undefined\", \"Clinical durability of next-generation RAF inhibitors remains untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 6, 7, 13]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 5, 6]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 8, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 3, 11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5, 6, 9, 10, 11, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 7, 16, 19, 20, 21]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 16]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 15]}\n    ],\n    \"complexes\": [\n      \"BRAF-CRAF heterodimer\",\n      \"BRAF homodimer\",\n      \"BRAF-KSR1 complex\",\n      \"RAF-MEK-ERK signaling complex\"\n    ],\n    \"partners\": [\n      \"CRAF\",\n      \"MEK1\",\n      \"MEK2\",\n      \"KSR1\",\n      \"KRAS\",\n      \"EP300\",\n      \"SIRT1\",\n      \"ARAF\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}